Arcutis Biotherapeutics/$ARQT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ticker
$ARQT
Sector
Primary listing
Employees
342
Headquarters
Website
ARQT Metrics
BasicAdvanced
$2.1B
-
-$0.74
1.85
-
Price and volume
Market cap
$2.1B
Beta
1.85
52-week high
$18.15
52-week low
$8.03
Average daily volume
1.8M
Financial strength
Current ratio
3.202
Quick ratio
2.862
Long term debt to equity
78.549
Total debt to equity
79.269
Interest coverage (TTM)
-4.71%
Profitability
EBITDA (TTM)
-80.072
Gross margin (TTM)
89.10%
Net profit margin (TTM)
-35.40%
Operating margin (TTM)
-32.58%
Effective tax rate (TTM)
-1.02%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
-13.46%
Return on equity (TTM)
-57.33%
Valuation
Price to revenue (TTM)
8.375
Price to book
15.15
Price to tangible book (TTM)
17.11
Price to free cash flow (TTM)
-27.134
Free cash flow yield (TTM)
-3.69%
Free cash flow per share (TTM)
-0.648
Growth
Revenue change (TTM)
99.50%
Earnings per share change (TTM)
-63.65%
3-year earnings per share growth (CAGR)
-47.53%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
Bulls say / Bears say
Patent litigation stay with Padagis extends Hatch-Waxman protection and preserves ZORYVE patent coverage until at least 2037, driving ARQT shares up 12.9% on April 2, 2025 after the settlement was announced (Reuters)
Positive Phase 3 data for roflumilast cream 0.05% in children aged 2–5 with atopic dermatitis showed durable efficacy and a favorable safety profile, leading ARQT stock to rise about 3.5% on August 28, 2024 (Reuters)
H.C. Wainwright initiated coverage of Arcutis with a Buy rating on December 30, 2024, signaling strong analyst endorsement from a well-known investment bank (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
ARQT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcutis Biotherapeutics stock?
Arcutis Biotherapeutics (ARQT) has a market cap of $2.1B as of September 13, 2025.
What is the P/E ratio for Arcutis Biotherapeutics stock?
The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of September 13, 2025.
Does Arcutis Biotherapeutics stock pay dividends?
No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Arcutis Biotherapeutics dividend payment date?
Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.